AbbVie Inc. (NYSE:ABBV) on Monday shared topline results from the Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) compared to placebo for upper limb essential tremor.

Upper limb essential tremor is a progressive movement disorder characterized by rhythmic, involuntary shaking of the hands and arms, most pronounced during action or specific postures.

The study met its primary endpoint, demonstrating statistically significant improvements in the Tremor Disability Scale-Revised (TREDS-R) of onabotulinumtoxinA compared to placebo at week 18.

Specifically, the onabotulinumtoxinA group showed a greater reduction in TREDS-R total unilateral score compared to placebo, with scores of -2.61 versus -1.61 (p=0.029). The study also met all six secondary endpoints.

Safety results were generally consistent with the well-established safety profile of onabotulinumtoxinA.

“No new pharmacological treatments ...